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Abstract
Background—Fatigue is a common symptom of liver disease but not well-characterized in 
patients with chronic hepatitis B virus (HBV).
Aims—We assessed the rate of fatigue using a validated instrument in patients with HBV and 
identified demographic, virologic, and clinical features associated with fatigue in a cross-sectional 
cohort study from the Hepatitis B Research Network (HBRN).
Methods—Participants were English and Spanish-speaking adults with chronic HBV who were 
not pregnant nor on treatment. Fatigue was measured using the PROMIS® Fatigue 7-item Short 
Form.
Results—The sample included 948 adults: median age 42; 51% female; 71% Asian; 74% college 
educated; 77% employed; 41% inactive HBV carriers; 36% with active chronic disease; and 2% 
with advanced fibrosis, defined as AST-Platelet Ratio Index (APRI) > 1.50. Patients with chronic 
HBV had a mean fatigue T-score of 46.8 ±SD=7.9, compared to a mean fatigue T-score of 50.0 ± 
10 in the U.S. general population (p<.0001). In univariate analyses, greater fatigue was associated 
with demographic and clinical features such as female sex, lower income, more comorbidities, 
higher APRI score, and poorer mental health (p<0.05). In multivariate analysis, female sex (p<.
001), poorer mental health (p <.001), APRI score (p=.005) and history of diabetes (p=.039) were 
the strongest independent predictors.
Conclusions—The frequency of fatigue in this large cohort of North American chronic HBV 
patients may be equal to or lower than that reported in the U.S. general population. Patients with 
advanced fibrosis, more comorbidities, and poorer mental health report worse fatigue.
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Introduction
Chronic infection with the hepatitis B virus (HBV) affects approximately 1.25 million 
individuals in North America, at least 10% of whom will develop cirrhosis, liver failure, or 
liver cancer in their lifetime(1). In addition to being at increased risk for liver-related 
mortality and morbidity, patients with chronic HBV may also have disease-related 
symptoms such as fatigue(2–6). Fatigue is the most commonly reported symptom in patients 
with chronic viral hepatitis and is associated with reductions in health-related quality of life 
(HRQOL)(3, 7, 8). In chronic hepatitis C, fatigue scores are higher than in the general 
population(7, 9) and often associated with demographic factors and poor mental health 
functioning(9–11). Moreover, patients with advanced liver disease or markers of cirrhosis 
have more pronounced decrements in HRQOL(8, 9, 11, 12).
Patient-reported outcomes such as fatigue are relatively under-studied in patients with 
chronic hepatitis B compared to those with hepatitis C. The majority of studies that 
specifically evaluate fatigue in HBV come from Asian or Middle Eastern countries where 
the findings may not be applicable to individuals living in North America because of socio-
cultural differences including health perceptions about what it means to have HBV(2, 13–
15). Studies assessing fatigue in HBV generally have been limited in sample size, and often 
have been part of larger studies that combined patients with various forms of liver disease(2, 
4, 13, 15, 16). Other studies have used single item questions, assessment of serious adverse 
events, or subscales of HRQOL instruments to measure fatigue(3). Almost all studies have 
had a primary emphasis on the broader construct of HRQOL which can be affected by 
numerous patient and environmental characteristics confounding the relationship with 
disease state(17). Symptoms, such as fatigue, are more directly associated with disease state, 
but often measured secondarily to HRQOL(2, 4, 14–16, 18). Taken together, standardized 
measures of fatigue have not been examined as a primary endpoint in any large North 
American cohort of patients with chronic HBV infection.
The National Institutes of Health (NIH) Patient-Reported Outcomes Measurement 
Information System® (PROMIS®) initiative has developed a comprehensive set of highly 
reliable, rigorously validated, precise tools to measure physical, mental, and social 
functioning and associated symptoms in the general U.S. population and across a wide range 
of chronic illnesses(19, 20). Fatigue is one of the core symptoms assessed by PROMIS 
because it is such a pervasive feature of many illnesses and treatments. The PROMIS fatigue 
surveys are highly reliable, and have been validated in several disease states(19, 21), 
countries, and ethnic groups(22, 23). Although not previously studied in chronic HBV 
infection per se, PROMIS measures have been used to measure patient-reported outcomes in 
other liver disease populations(24–26).
The Hepatitis B Research Network (HBRN), a cooperative network of investigators from 
clinical centers across the U.S. and Canada, provided a unique opportunity to evaluate 
fatigue in patients representing all phases of chronic HBV infection. The specific aims of the 
current HBRN study analysis were to (a) assess fatigue using one of the PROMIS short form 
surveys and (b) identify clinical, laboratory and demographic factors associated with fatigue 
in a large multi-ethnic North American population.
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Materials and Methods
Study Design
This is a large, multi-center cross-sectional study analyzing data collected from patients 
enrolled in the HBRN Cohort Study. The HBRN is a cooperative network of investigators 
from 21 geographically distinct clinical centers across the United States and one in Canada, 
a data coordinating center, virology testing laboratory and immunology center. The goal of 
the HBRN is to conduct clinical, scientific, epidemiological and therapeutic research in 
acute and chronic hepatitis B in both adult and pediatric patients who reside in North 
America (27). All protocols were approved by the Steering Committee and the Institutional 
Review Boards or Research Ethics Boards of the participating sites, and all participants 
provided written informed consent.
Participants
The HBRN observational cohort study enrolls participants with hepatitis B who are above 
the age of 2 years, are not on antiviral therapy and do not have decompensated chronic 
hepatitis B nor hepatocellular carcinoma at enrollment. All consenting participants undergo 
an initial evaluation with collection of demographic information and medical history. In 
addition, routine laboratory results and virologic testing are done at baseline and at weeks 
12, 24, 48, 72, 96, 120, and 144. The NIH PROMIS Fatigue 7-item Short Form (Fatigue SF) 
was introduced into the observational cohort study after recruitment had begun, and 
therefore fatigue was assessed at 48 weeks following the baseline visit. In those participants 
already completing their 48 weeks visit, fatigue was assessed at the week 72 visit. 
Administration of the Fatigue SF was limited to adults above the age of 18 years who could 
speak or read English or Spanish. Among 1654 adult patients who were enrolled in the 
HBRN at the time of this study, 1118 participants completed the Fatigue SF (893 at week 48 
and 225 at week 72). The reasons for not completing the Fatigue SF included study 
discontinuation (n=163), not reaching week 48 or 72 (n=26), lack of IRB approval (n=12 for 
whom a site did not have the Fatigue SF approved by IRB prior to week 48 or 72 of the 
study), language barrier (n=175), and incompletion or missed visit (n=160). Of the 1118 
who completed the form, 170 were excluded from the current analyses because they were 
being treated for hepatitis B, were pregnant, or had acute HBV infection. The remaining 948 
patients were included in the analytic dataset. The proportion of patients recruited from each 
center was approximately 50% (range: 22%–73%). Demographic data from the baseline 
visit and clinical and virological data collected at the same visit as the Fatigue SF 
assessment were used for these analyses. If covariates were not available at the same time 
point as the Fatigue SF, values from the previous time point were carried forward.
Measures
Fatigue—The PROMIS Fatigue 7-item Short Form (SF) consists of seven questions that 
assess the experience of fatigue (e.g., “tired”, “run out of energy”) and interference of 
fatigue on daily activities (e.g., “work”, “take a bath or shower”) over the past 7 days (see 
Appendix 1; http://www.nihpromis.org/science/PubsDomain/Fatigue_adult.aspx). The 
PROMIS Fatigue 7-item SF includes a subset of items from a larger PROMIS item bank of 
fatigue items for which the items were selected to capture frequency of fatigue experience 
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and interference (e.g., How often did you feel tired?) with five response options ranging 
from 1 (“never”) to 5 (“always”) (28). Responses are summed so that the final raw score 
ranges from 7 (lowest possible) to 35 (highest possible). NIH PROMIS provides a scoring 
table to translate the total raw score into a standardized T-score, which has been calibrated 
in the US general population to have a mean of 50 and a standard deviation (SD) of 10. The 
PROMIS T-score metric was based on a sample of 21,133 participants whose internet 
responses were used to calibrate and derive final T-scores, weighted to the U.S. census 
norms from 2000(19, 20, 29). A subject with a T-score of 40 is one SD below, and a subject 
with a T-score of 60 is one SD above the U.S. general population mean. Higher fatigue T-
scores indicate higher degrees of fatigue. In previous studies, the Fatigue SF correlated with 
the full item bank of fatigue items (r = 0.76), correlated with other measures of fatigue (r = .
89 –.95) and the reliability of measurement was greater than 0.91 for scores 2 SD below and 
4 SD above the mean (19).
Demographic, clinical and virological features—The Fatigue SF scores were 
analyzed overall in the cohort as well as by multiple demographic features including age, 
sex, race, marital status, education, employment, income, continent of birth, and years living 
in the United States and Canada. Clinical features considered in the analyses of fatigue 
scores included serum alanine aminotransferase (ALT), total bilirubin, albumin, body mass 
index (BMI), advanced fibrosis as measured by the AST-Platelet Ratio Index (APRI), 
medication type, and medical comorbidities (i.e., diabetes, hypertension, hyperlipidemia, 
and other liver diseases such as alcoholic liver disease, non-alcoholic liver disease, 
autoimmune liver disease, and hepatitis C and D infections). Virological factors analyzed for 
association with fatigue included clinically-assigned HBV phenotype, presence or absence 
of HBeAg, HBV DNA level, duration of infection, and presumed source of infection. The 
HBV phenotype was assigned by clinicians at enrollment based upon common conventions 
using HBV DNA and ALT levels. The guidelines established by the HBRN are as follows: 
Inactive HBsAg carriers had HBsAg without HBeAg, normal ALT levels and no or minimal 
HBV DNA levels in serum (<1000 IU/mL). Immune active chronic hepatitis B was defined 
by presence of HBsAg and raised ALT levels with moderate or high levels of HBV DNA in 
serum (>10,000 IU/mL) and were also divided into those with and without HBeAg. Immune 
tolerant chronic hepatitis B was defined by presence of HBsAg, HBeAg and high levels of 
HBV DNA in serum, with normal ALT levels. Patients not fitting into any of these 3 
patterns were considered “indeterminate.” Since previous studies in chronic hepatitis C 
demonstrated that fatigue is often associated with mental health functioning, the Medical 
Outcomes Study 36-item Short Form (MOS SF-36) Mental Health Functioning subscale was 
used as one of the clinical correlates(30). The Mental Health Functioning subscale includes 
5 items which assess feeling “down in the dumps,” “nervous,” “blue/sad,” “happy,” and 
“peaceful” in the last 7 days; thus the subscale is not contaminated with items that measure 
fatigue or somatic symptoms. Using an algorithm, the raw score is translated into a norm-
based standardized T-score, with a mean of 50 and a standard deviation of 10. Higher scores 
indicate better mental health functioning.
Data Analytic Plan—The raw scores from the Fatigue SF were translated into 
standardized T-scores which were calculated using the public software package 
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PROMIScore (http://www.nihpromis.org/resources/resourcehome). All PROMIS measures, 
including the Fatigue SF, were derived from larger item banks which were evaluated in an 
initial sample of 21,133 respondents (29). The sample was weighted to have the same 
distribution of demographic variables as that in the 2000 U.S. Census (29, 31). After 
calculation of the T-score, a test of whether the mean T-score deviated from 50 was 
conducted using a two-sided t-test. Subsequently, Fatigue T-scores were described using 
means, standard deviations, and confidence intervals. Covariates were chosen based upon 
the previous literature on fatigue in liver disease patients and the clinical judgment and 
experience of the working group. Across levels of categorical covariates, T-scores were 
compared using t-tests for two-level variables or analysis of variance F-tests for variables of 
three or more levels. Linear regression analysis was used to assess the association between 
fatigue scores and continuous covariates. Multiple linear regression was employed to 
identify independent predictors of fatigue significant at p<0.05. Age, race, APRI, and viral 
load were forced into the multivariable model considering their clinical importance. For 
other covariates, variables significant at p=0.10 in the univariable regression were 
considered for inclusion in the multivariable regression model and a step-wise variable 
selection method was used to select a final model. Variables omitted (due to their p-values 
being greater than 0.10 in the univariable analysis) were checked further by including them 
individually in the final model to see whether they become statistically significant when 
adjusted for other variables.
Results
Participant Characteristics
The characteristics of the 948 participants are summarized in Table 1. Over 88% of 
participants who completed the fatigue survey spoke English as a primary language; the 
remaining 12% spoke English as a second language and were able to complete the survey. 
Fifty one percent (n=451) of participants were female, the median age was 42 years, and the 
median duration of HBV infection 31 years. Participants were predominantly Asian (71%) 
with only 13% of Caucasian race. The majority (74%) had some college education or above. 
Participants were primarily employed (77%).
HBV phenotype was clinician-assigned at the time of enrollment into HBRN: 40.7% were 
considered inactive carriers, 36% had chronic hepatitis B with disease activity (9.9% with 
HBeAg and 25.6% without HBeAg), 10.1% had immune tolerant hepatitis B, and 13.6% 
were designated as “indeterminate”. The median HBV DNA was 3.4 log10 IU/mL, the 
median ALT was 30 U/L, and 2% of participants had APRI scores (>1.5) suggestive of 
advanced fibrosis or cirrhosis. Comorbid conditions were not very frequent with only 27.8% 
of participants having another medical condition besides hepatitis B. The SF-36 Mental 
Health Functioning subscale norm-based score had a median value of 54.2, with the middle 
50% of participants being between 47.2 and 58.5.
Evaluation of fatigue in the cohort
There was excellent internal consistency (over Cronbach’s alpha = 0.84) for the fatigue short 
form with individual item’s alpha ranging from 0.79 to 0.89. In the HBRN cohort the mean 
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Fatigue raw score was 14.13 (SD=4.48) and the transformed standardized T-score was 46.8 
(95% CI 46.3–47.3), which was lower than that of the reference mean for the U.S. general 
population (T=50). Prior studies suggest that one-half of a SD is equivalent to a moderate 
effect size and the minimally important difference (MID) in PROMIS scores range from 2–5 
points (32). Although the 3.2 difference between the HBRN and PROMIS samples was 
statistically significant (p<0.0001), it may or may not represent a clinically meaningful 
difference. The distribution of the fatigue scores in the HBRN cohort is shown in the 
histogram and density plot of Figure 1, with 33.3% (95% CI: 30.3%–36.4%) of participants 
having a score greater than the average U.S. fatigue T-score of 50, and 15.4% (95% CI: 
13.2% – 17.9%) of participants having fatigue T-scores above 55.
Unadjusted and adjusted associations between fatigue and demographic and clinical 
patient characteristics
In unadjusted analyses, female sex, not being married, not being employed, higher BMI, 
lower income, higher APRI, being born in North or South America, currently taking 
medications, having co-morbid conditions (specifically, hyperlipidemia, diabetes, and other 
liver diseases such as hepatitis C or D), and lower mental health functioning were all 
significantly (p<0.05) associated with higher fatigue scores (Table 1). In particular, mean 
fatigue scores were 2.5 points higher in females than males, 1.9 points higher in those not 
employed compared to those who were employed, and 3.1 points higher in patients 
widowed, divorced, or separated compared to those who were married.
Among clinical laboratory variables analyzed as continuous variables, serum ALT, AST, 
bilirubin and alkaline phosphatase levels were not significantly associated with fatigue 
scores. The calculated APRI score, however, was significantly associated with fatigue 
scores, being on average 6.3 points higher in participants with APRI >1.5 (T=53) compared 
to those with levels of <=0.5 (T=46.7) or 0.5–1.5 (T=47.0). Serum albumin levels were also 
significantly associated with fatigue scores, with a 2.1 point reduction in fatigue for a 1 g/dL 
increase in albumin. Notably, there were no significant associations between fatigue scores 
and any virological feature of hepatitis B such as HBeAg status and HBV DNA levels. In 
addition, fatigue scores were almost identical among the clinically-assigned HBV 
phenotypes with no differences between inactive HBsAg carriers (46.9) compared to those 
with HBeAg positive (46.1) or HBeAg negative immune active disease (47.1), or immune 
tolerant hepatitis B (45.9). In contrast, the presence of other medical comorbidities and 
worse mental health functioning were both significantly associated with higher levels of 
fatigue. Participants with one or more comorbidities had 1.6 points higher average fatigue 
scores compared to those without any comorbidities. For every 10-point decrease in the 
mental health functioning score, the mean fatigue score increased by 4.6 points.
Table 2 shows results for adjusted regression models with race, age, APRI, and viral load 
forced into the model. Sex, mental health functioning, and having a history of diabetes 
remained significant independent predictors of fatigue. In the adjusted analysis, the 
estimated mean fatigue score for females was 2.18 units (95% CI: 1.29 – 3.06) higher than 
for males (p<0.0001). The estimated mean fatigue score for those with APRI >1.50 
(advanced fibrosis) was 4.41 units (95% CI: 1.32 – 7.50) higher than for those with APRI ≤ 
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0.50 (p=.005). Those with a history of diabetes had a mean fatigue score that was 2.22 (95% 
CI: 0.11 – 4.32) units higher than those without a history of diabetes (p=0.039). Finally, as 
mental health functioning deteriorated, mean fatigue scores increased (Figure 2). A 10 unit 
decrease in mental health functioning was associated with a 4.4 (95% CI: 4.0 – 4.9) unit 
increase in mean fatigue score (p<0.0001).
Discussion
Fatigue is a common symptom of many medical conditions including diseases of the liver. 
In this study, fatigue was assessed using a reliable and validated instrument in a large multi-
ethnic cohort of patients with chronic HBV infection residing in North America. We utilized 
the PROMIS Fatigue 7-item short form to measure the frequencyand intensity of fatigue. 
The PROMIS measure was selected because of its precision in measuring the 
unidimensional construct of fatigue without being confounded by items that tap other 
symptoms (e.g., depression) or domains (e.g., HRQOL). Further, it is short, easily utilizable, 
patient-friendly, and has been applicable to a wide range of disease states, including liver 
disease(26). The main findings of this study suggest that fatigue is unrelated to most 
virologic and disease markers of HBV, however it is associated with liver disease severity 
(i.e., APRI score suggestive of advanced fibrosis), as well as female sex, mental health 
functioning, and comorbidities such as diabetes.
Several virologic and disease markers of HBV were evaluated in this study, including 
clinically-assigned HBV phenotype, HBeAg status, HBV DNA levels, serum 
aminotransferase levels and APRI score. Approximately 50% of the study cohort had 
immune active HBV disease, however fatigue was not more severe among these patients 
compared to those with immune inactive or immune tolerant disease phenotypes. The only 
clinical variable associated with fatigue in the multivariate model, was evidence of advanced 
liver disease with APRI score of > 1.5. The relationship between severity of liver disease 
and fatigue thus far in the literature has been equivocal, with one study demonstrating no 
association(13), but a few suggesting that patients with cirrhosis experience greater 
fatigue(2, 11, 33) and worse quality of life(5). In a similar population, fatigue levels of 
patients infected with chronic hepatitis C were not associated with Ishak fibrosis score on 
liver biopsy, the gold standard for diagnosis of cirrhosis(34). The finding that only an APRI 
score of >1.5 is associated with fatigue suggests that serious fatigue issues are uncommon in 
chronic HBV infection unless advanced fibrosis is present. These findings reinforce the need 
for routine screening for hepatitis B in high risk populations, because patients are unlikely to 
have symptoms indicative of the presence of liver disease. The absence of symptoms of 
fatigue also places a burden on the treatment for this disease, the endpoints of which should 
be prevention of disease progression, not necessarily amelioration of symptoms. The lack of 
association with most virologic or clinical markers indicates that chronic hepatitis B is 
generally an asymptomatic disease; however patient-reported fatigue may indicate the 
presence of advanced fibrosis.
The single, strongest predictor of higher fatigue levels was low mental health functioning, a 
SF-36 subscale that taps into emotions such as feeling down in the dumps, nervous, blue, 
sad, happy, and peaceful while not tapping into somatic items, such as fatigue. Other studies 
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have produced similar findings in chronic hepatitis B and C with measures of 
neuropsychiatric comorbidities, anxiety, and depression predicting higher fatigue levels(4, 5, 
10, 11, 13, 14). Collectively, these findings provide important insight into specific patients 
who may subjectively experience greater fatigue, namely those with higher rates of 
depressed or anxious mood.
Importantly, higher levels of fatigue were found in women compared to men. This finding is 
consistently documented in previous studies, including those using the PROMIS fatigue 
survey in both normal control and in disease populations (35–37) and in women infected 
with chronic hepatitis C(11). Predisposing vulnerabilities for women (e.g., endocrine and 
stress-related factors and social-contextual determinants) have been proposed to explain this 
phenomenon, however, it remains a commonly observed but not well understood association 
(35).
Several unique aspects of the current study, compared to the existing literature, are 
noteworthy. Previously, close examination of fatigue severity in patients with chronic 
hepatitis B has been hampered by relatively small sample sizes or studies that combine 
hepatitis B with other chronic liver diseases(6, 38, 39). In addition, most studies have not 
focused on the unique situation in North America with its diverse populations reflecting 
different sources of infection, varying genotypes and distinct clinical courses of this chronic 
infection(40). One qualitative study focused on symptoms among U.S. patients with chronic 
hepatitis B, but the cohort was comprised largely of non-Asian patients who now represent 
the minority of patients with this disease in the United States(3). Moreover, the primary 
emphasis has been on understanding the effect of chronic HBV infection on the broader 
construct of HRQOL which is influenced by many patient and environmental 
characteristics(17), while specific symptoms such as fatigue have been measured 
secondarily(2, 4, 14–16, 18). Therefore, the current study broadens our knowledge of 
patient-reported fatigue in a predominately Asian cohort chronically infected with HBV and 
residing in North America. It is possible that differences between the HBRN and PROMIS 
samples, such as race, education, and comorbidities partially explain the statistical 
differences in fatigue scores, although it remains unclear whether this difference is clinically 
meaningful. The HBRN and control PROMIS cohorts differed prominently in racial 
distribution (74% Asian vs 1%), and one might speculate that Asians experience less fatigue 
than Caucasians. However, we found no significant univariate differences in mean fatigue 
scores among the Asian (T=46.7), African-American (T=46.2) or Caucasian (T=47.9) 
patients in the HBRN cohort. Moreover, all three racial groups had median fatigue scores 
lower than the general US population, suggesting that other factors, not race, likely underlie 
these differences. On variables available for comparison, the most important difference 
between the two samples may relate to the fewer comorbidities in the HBRN population 
(27%) compared to the general population in the U.S. (72%). Nonetheless, no meaningful 
comparisons can truly be made between the PROMIS sample, which was weighted to have 
the same distribution of demographics as that in the 2000 U.S. Census, and the HBRN 
sample of patients who are predominantly Asian, more educated, and have fewer 
comorbidities.
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A few limitations of this study should be noted. Given the specific patient characteristics of 
this cohort, these findings may not be generalizable to patients with more advanced liver 
disease or those engaged in active HBV treatment, Non-Asian patients, or individuals 
residing in other countries where socio-cultural perceptions about having HBV or liver 
disease may differ. Only 2% of this sample had advanced fibrosis or cirrhosis as estimated 
by APRI. This may have been because the HBRN network did not enroll patients with 
decompensated cirrhosis or patients who were already on HBV treatment. Further, patients 
who were on HBV treatment at the time of fatigue assessment were excluded from the 
current study in order to focus specifically on fatigue that was not caused by treatment side 
effects. Of the 130 participants who were excluded from this study due to being on 
treatment, and who had an APRI score, 12 (9%) had APRI scores > 1.5, substantially higher 
than the 2% reported in our sample. Therefore, the average fatigue level likely would have 
been higher had the sample included a greater number of patients with advanced liver 
disease or on HBV treatment. In this study, we employed APRI as a surrogate for liver 
histology since liver biopsies were neither necessary nor warranted in many study 
participants, and when available, were rarely concurrent with administration of the PROMIS 
fatigue survey. Also, only patients who were English or Spanish speaking were recruited for 
this study because the PROMIS Fatigue Short form had yet to be translated and tested in 
other languages. That said, less than a quarter of otherwise eligible patients failed to 
complete the fatigue instrument due to language barriers. By assessing fatigue at weeks 48 
and 72 weeks, we likely missed patients initially diagnosed with more severe disease who 
required immediate treatment and hence were excluded from these analyses. Our study also 
did not collect information on anti-depressant or anti-anxiety medication; therefore, the 
analysis could not be adjusted for the use of these medications. Finally, the external validity 
of the PROMIS fatigue instrument (or any other fatigue instrument) has not been previously 
established in individuals with chronic HBV infection or in those from Asian American 
descent. We chose the PROMIS Fatigue instrument due to its rigorous reliability and 
validity (e.g., construct, content, and concurrent validity), correlation with items from the 
larger fatigue bank and other measures of fatigue (e.g., SF-36 Vitality Scale), validity in 
other medical populations, and to contribute to the overall mission of the NIH PROMIS 
initiative (20, 41–45). Future studies of fatigue in patients with HBV should include 
longitudinal analysis of fatigue before, during and after HBV treatment to evaluate trends 
over time, and assessment of other moderator and mediator variables to better understand 
which patients, and by which pathways, HBV may be related to fatigue.
In conclusion, in this cohort of North American adults participating in the HBRN study, 
higher fatigue levels are associated with more advanced liver disease and more comorbid 
conditions, such as diabetes, but no other disease or virologic markers. Women and patients 
who experience poorer mental health functioning, such as symptoms of depression or 
anxiety, also appear to be prone to higher levels of fatigue. In patients who complain of 
fatigue during the clinical encounter, providers should be suspicious of advanced fibrosis or 
mental health issues, and refer accordingly for further evaluation.
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Figure 1. 
Distribution of fatigue T-score in HBV patients in the cohort.
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Figure 2. Association between Fatigue T-Score and Mental Health Functioning
Scatter plot of Fatigue T-Score vs SF-36 Mental Health Functioning subscale norm-based 
score with regression line. Each circle represents a participant or overlapping of participant 
points.
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Table 1
Participant characteristics and unadjusted associations with fatigue, N=948
Variable Median(25th:75th) n(%) Unadjusted Mean/Slope** (95% CI) p-value
Age N=945
42.0 (34.0 : 52.0) 0.03 (−0.01, 0.07) 0.21
Sex N=940
 Male 462 (49.1%) 45.5 (44.79, 46.21) <0.001
 Female 478 (50.9%) 47.97 (47.27, 48.67)
Race N=937 0.19*
 Asian 666 (71.1%) 46.67 (46.07, 47.27)
 African American/Other 154 (16.4%) 46.17 (44.93, 47.42) 0.48
 Caucasian 117 (12.5%) 47.9 (46.47, 49.33) 0.12
Marital Status N=925 0.001*
 Married or living in a marriage-like relationship 628 (67.9%) 46.38 (45.76, 46.99)
 Never married 201 (21.7%) 46.71 (45.62, 47.79) 0.6
 Widowed, divorced, or separated 96 (10.4%) 49.51 (47.94, 51.07) <0.001
Education N=932
 Some grade school through HS 242 (26.0%) 46.82 (45.83, 47.82) 0.91
 Some college and above 690 (74.0%) 46.75 (46.16, 47.34)
Employment N=936
 Part-time/full-time 722 (77.1%) 46.37 (45.79, 46.94)
 Homemaker/retired/unemployed/other 214 (22.9%) 48.22 (47.17, 49.27) 0.002
Income N=776 0.003*
 $0 to $49.9K 338 (43.6%) 47.8 (46.97, 48.64)
 $50K to $99.9K 212 (27.3%) 47.09 (46.04, 48.14) 0.3
 100K to $199.9K 161 (20.7%) 45.56 (44.35, 46.76) 0.003
 $200K+ 65 (8.4%) 44.91 (43.01, 46.8) 0.006
Continent at Birth N=937 0.002*
 Asia 606 (64.7%) 46.78 (46.16, 47.4)
 North/South America 201 (21.5%) 47.96 (46.88, 49.05) 0.06
 Africa 92 (9.8%) 44.1 (42.5, 45.7) 0.002
 Europe/Australia 38 (4.1%) 46.49 (44, 48.97) 0.82
Years in US/Canada N=856 0.07*
 <=10 years ago 192 (22.4%) 46.03 (44.91, 47.14) 0.05
 >10–20 years ago 208 (24.3%) 46.13 (45.06, 47.2) 0.07
 >20 years ago 456 (53.3%) 47.34 (46.61, 48.06)
ALT (IU/L) N=942
30.0 (21.0 : 45.0) 0 (−0.01, 0.01) 0.56
TBili (mg/dL) N=940
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Variable Median(25th:75th) n(%) Unadjusted Mean/Slope** (95% CI) p-value
0.6 (0.5 : 0.9) −1.21 (−2.64, 0.22) 0.1
Albumin (g/dL) N=937
4.3 (4.1 : 4.5) −2.08 (−3.62, −0.55) 0.008
HBV DNA (log10 IU/mL) N=945
3.4 (2.4 : 4.9) −0.14 (−0.35, 0.07) 0.2
BMI (kg/m2) N=934
24.1 (21.8 : 27.1) 0.11 (0.01, 0.21) 0.029
Years of HBV Infection N=641
31.0 (20.0 : 42.0) 0.05 (0.01, 0.09) 0.008
Phenotype N=938 0.61*
 Inactive carrier state 382 (40.7%) 46.91 (46.12, 47.7)
 HBeAg negative chronic hepatitis B 240 (25.6%) 47.14 (46.15, 48.14) 0.72
 Indeterminate 128 (13.6%) 46.83 (45.46, 48.2) 0.92
 Immune tolerant chronic hepatitis B 95 (10.1%) 45.85 (44.26, 47.44) 0.24
 HBeAg positive chronic hepatitis B 93 (9.9%) 46.08 (44.48, 47.69) 0.36
APRI (AST-platelet-ratio index) N=887 0.004*
 <=0.50 704 (79.4%) 46.67 (46.09, 47.25)
 >0.50–1.50 165 (18.6%) 47.03 (45.82, 48.23) 0.6
 >1.50 18 (2.0%) 52.99 (49.34, 56.64) <0.001
Presumed Source of Hepatitis B N=948 0.86*
 Vertical transmission 415 (43.8%) 46.67 (45.91, 47.44)
 Horizontal transmission 175 (18.5%) 46.49 (45.31, 47.67) 0.8
 Sexually transmitted 37 (3.9%) 47.79 (45.23, 50.35) 0.41
 Other 70 (7.4%) 47.38 (45.52, 49.25) 0.49
 Unknown/Missing 251 (26.5%) 46.77 (45.79, 47.75) 0.88
Currently Taking Any Prescription Medication N=945
 Yes 224 (23.7%) 47.89 (46.85, 48.92) 0.017
 No 46.44 (45.87, 47.02)
Medical Comorbidities N=945
 At least one 263 (27.8%) 47.96 (47, 48.91) 0.005
 None 46.34 (45.74, 46.93)
Hx Diabetes N=945
 Yes 46 (4.9%) 50.43 (48.15, 52.71) 0.001
 No 46.6 (46.09, 47.12)
Hx Hypertension N=945
 Yes 151 (16.0%) 47.77 (46.51, 49.03) 0.1
 No 46.6 (46.05, 47.15)
Hx Hyperlipidemia N=944
 Yes 128 (13.6%) 48.77 (47.4, 50.13) 0.002
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Variable Median(25th:75th) n(%) Unadjusted Mean/Slope** (95% CI) p-value
 No 46.48 (45.94, 47.02)
Hx Liver Disease N=948
 Yes 61 (6.4%) 48.81 (46.82, 50.8) 0.034
 No 46.60 (46.07, 47.13)
SF-36 Mental Health Functioning N=940
54.2 (47.2 : 58.5) −0.46 (−0.5: −0.41) <0.001
*for testing equality of T-scores across all categories
**
For discrete variables, unadjusted category mean fatigue score. For continuous variables, change in mean fatigue score per unit change in 
variable.
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Table 2
Adjusted associations between fatigue and participant characteristics (n=876)
Variable Regression Coefficient (95% CI) p-value
Race 0.09
 African-American/Other vs Asian −1.31 (−2.51, −0.12) 0.032
 Caucasian vs Asian −0.63 (−2.00, 0.74) 0.37
Age 0.01 (−0.02, 0.05) 0.48
APRI 0.012*
 >1.50 vs <=0.50 4.41 (1.32, 7.50) 0.005
 >0.50–1.50 vs <=0.50 0.74 (−0.41, 1.89) 0.21
HBV DNA (log10 IU/mL) −0.15 (−0.35, 0.05) 0.15
Female vs Male 2.18 (1.29, 3.06) <0.001
History of Diabetes 2.22 (0.11, 4.32) 0.039
SF-36 Mental Health Functioning Score −0.44 (−0.49, −0.40) <0.001
Note:
*for testing equality of T-scores across all categories
Race, Age, APRI, and HBV DNA were forced into model
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